Citius Oncology (CTOR) Income from Continuing Operations (2023 - 2026)

Citius Oncology (CTOR) has 4 years of Income from Continuing Operations data on file, last reported at 26609695.0 in Q1 2026.

• On a quarterly basis, Income from Continuing Operations fell 243.99% year-over-year to 26609695.0 in Q1 2026; TTM through Mar 2026 was 42510376.0, a 11.01% decrease from a year earlier, with the FY2025 full-year figure at 24761369.0, down 17.08% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 26609695.0, down from 5534069.0 in the prior quarter.
• Over the last five years, Income from Continuing Operations for CTOR reached as high as 147922.0 in Q1 2023 and fell as low as 26609695.0 in Q1 2026.
• Historically, Income from Continuing Operations has averaged 7557557.58 across 4 years, with a median of 5452012.5 in 2025.
• Across the five-year window, Income from Continuing Operations tumbled 7083.92% in 2024 and jumped 62.54% in 2025, its largest moves.
• Year by year, Income from Continuing Operations stood at 4727403.0 in 2023, then plunged by 40.86% to 6659205.0 in 2024, then grew by 16.9% to 5534069.0 in 2025, then tumbled by 380.83% to 26609695.0 in 2026.
• Per Business Quant data, the three most recent Income from Continuing Operations figures were 26609695.0 in Q1 2026, 5534069.0 in Q4 2025, and 4996656.0 in Q3 2025.